Nateglinide
From Wikipedia, the free encyclopedia
| Image:Nateglinide.svg | |
| Nateglinide
| |
| Systematic (IUPAC) name | |
| 3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid | |
| Identifiers | |
| CAS number | 105816-04-4 |
| ATC code | A10BX03 |
| PubChem | 60026 |
| DrugBank | APRD00593 |
| Chemical data | |
| Formula | C19H27NO3 |
| Mol. weight | 317.423 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 98% |
| Metabolism | ? |
| Half life | 1.5 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Nateglinide (INN, trade name Starlix®) is a drug for the treatment of type 2 diabetes.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs and is sold by Novartis.
[edit] Pharmacology
Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.
[edit] Dosage
Nateglinide is delivered in tablet form.
[edit] External links
- Starlix - website of the manufacturer.
- How Nateglinide Works - website of the manufacturer.
